Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discusses prospective clinical trials as the gold standard of clinical decision-making and examines the infrastructure needed for future cancer research. (Abstract PS 3)
Daniel A. Hamstra, MD, PhD, of Texas Oncology, discusses phase III findings on the use of an absorbable hydrogel spacer designed to decrease rectal toxicity and improve bowel quality of life for patients with prostate cancer. (Abstract LBA-6)
Takeshi Kodaira, MD, PhD, of Aichi Cancer Center Hospital, discusses the final analysis of a randomized phase III trial of accelerated vs conventional fractionation radiotherapy for glottic cancer of T1-2N0M0. (Abstract LBA-8)
Bruce D. Minsky, MD, of The University of Texas MD Anderson Cancer Center and Chairman of the ASTRO Board, discusses top papers presented at this year’s Annual Meeting.
Brian Kavanagh, MD, MPH, of the University of Colorado at Denver and ASTRO’s incoming President, discuss his goals for the Society in 2017.
Thomas J. Lynch, Jr, MD, of Massachusetts General Hospital, summarizes his keynote lecture on whether we are any closer to curing lung cancer with targeted treatments. (Keynote Address 2)
